H.R. 5423 115th Congress House

GEDI Act

Official title: To provide grants to better understand and reduce gestational diabetes, and for other purposes.

Introduced: April 2, 2018 See on congress.gov

Health Advisory bodiesDigestive and metabolic diseasesHealth information and medical recordsHealth programs administration and funding

More subjectsShow fewer subjects

Health promotion and preventive careMedical researchMedical tests and diagnostic methodsSex and reproductive healthWomen's health

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Apr 2, 2018

Referred to the House Committee on Energy and Commerce.

Apr 2, 2018

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Latest action April 2, 2018

Referred to the House Committee on Energy and Commerce.

Plain-English summary Congressional Research Service

Gestational Diabetes Act of 2018 or the GEDI Act

This bill amends the Public Health Service Act to direct the Centers for Disease Control and Prevention (CDC) to develop a multisite gestational diabetes research project to expand and enhance surveillance data and public health research on gestational diabetes.

The CDC must expand and intensify public health research on gestational diabetes.

The CDC must: (1) award grants for demonstration projects to reduce the incidence of gestational diabetes, the recurrence of such disease in subsequent pregnancies, and the development of type 2 diabetes in women with a history of gestational diabetes; and (2) work with state and Indian tribal-based diabetes prevention and control programs assisted by the CDC to encourage postpartum follow-up after gestational diabetes to reduce the incidence of gestational diabetes and its recurrence, the development of type 2 diabetes in at-risk women, and related complications.

Related & companion bills 2